All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2024-09-23T16:33:44.000Z

FDA approves Isa-VRd for transplant-ineligible NDMM

Sep 23, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in newly diagnosed MM.

Bookmark this article

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.1

This approval was based on data from the phase III IMROZ (NCT03319667) trial.

IMROZ pivotal data2

IMROZ, an open-label, phase III trial, enrolled adult patients with newly diagnosed multiple myeloma ineligible for transplant. Patients were randomly assigned 3:2 to receive isatuximab-VRd (Isa-VRd) or VRd alone. The primary endpoint was progression-free survival (PFS), with secondary endpoints including complete response, measurable residual disease negativity, and overall survival (OS).

  • At a median follow-up of 59.7 months, median primary endpoint of PFS was not reached in the Isa-VRd arm and was 54.3 months in the VRd arm.
  • Key secondary outcomes in the Isa-VRd arm vs VRd arm were as follows:
    • The overall response rate and the complete response or better rate were 91.3% and 74.7% vs 92.3% and 64.1%
    • The MRD negativity rates were 58.1% vs 43.6%
    • Sustained MRD negativity at ≥12 months were 46.8% vs 24.3%
    • The 60-month OS rates were 72.3% vs 66.3%
  • Common adverse effects included infections, diarrhea, fatigue, neuropathy, and pneumonia.

  1. U.S. Food and Drug Administration. FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-bortezomib-lenalidomide-and-dexamethasone-newly-diagnosed-multiple?utm_medium=email&utm_source=govdelivery. Published Sep 20, 2024. Accessed Sep 23, 2024.
  2. OncLive. FDA approves isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma. https://www.onclive.com/view/fda-approves-isatuximab-plus-vrd-for-newly-diagnosed-transplant-ineligible-multiple-myeloma. Published Sep 20, 2024. Accessed Sep 23, 2024.

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 43 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox